Every material Form 8-K TALPHERA, INC. has filed with the SEC since May 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Talphera reported no revenue for the second quarter of 2026 and a net loss of $4.3 million, or $0.06 per share, versus a net loss of $3.5 million, or $0.10 per share, a year earlier. The dollar loss grew, but the per-share loss narrowed as weighted shares rose to 75.5 million from 34.5 million. The company said NEPHRO CRRT study enrollment reached 75%, with completion expected this year.
Net loss of $4.3 million, or $0.06 per share, for Q2 2026, compared with $3.5 million, or $0.10 per share, for Q2 2025
Combined R&D and SG&A expenses of $3.9 million, up from $3.7 million, mainly due to higher Niyad development expenses
Cash, cash equivalents and investments of $17.1 million at June 30, 2026, down from $20.4 million at December 31, 2025
NEPHRO CRRT study 75% enrolled; company regained Nasdaq compliance with the $1 bid price rule
At its June 22, 2026 annual meeting, Talphera stockholders elected Marina Bozilenko, Joseph Todisco and Mark Wan as Class III directors, ratified BPM LLP as the auditor for 2026, and approved the advisory vote on executive pay. Stockholders also approved amended and restated versions of the 2020 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan, which the company filed as exhibits.
31,436,937 of 51,899,648 eligible shares were represented at the meeting, as of the April 24, 2026 record date.
Marina Bozilenko received 23,303,306 votes for and 400,888 withheld; Joseph Todisco and Mark Wan were also elected to terms ending at the 2029 annual meeting.
The 2020 Equity Incentive Plan was approved with 22,602,504 votes for and 1,068,623 against.
The 2011 Employee Stock Purchase Plan was approved with 23,020,334 votes for and 657,322 against.
Talphera reported a first quarter 2026 net loss of $2.6 million, or $0.04 per share, roughly flat in dollars from a year earlier but improved per share after a larger share count and a $1.2 million warrant liability gain. Operating expenses rose to $3.9 million from $2.9 million, and the company reported no revenue compared with $27 thousand a year earlier, so the operating loss widened. The company said NEPHRO CRRT enrollment has exceeded the 50% milestone and it expects study completion later in 2026.
Q1 2026 net loss was $2.6 million, or $0.04 per share, versus $2.6 million, or $0.10 per share, in Q1 2025
Loss from operations was $3.9 million versus $2.9 million a year earlier; revenue was zero versus $27 thousand
Cash and investments were $21.1 million at March 31, 2026, up from $20.4 million at December 31, 2025
In March 2026 the company closed a $4.1 million third tranche of its March 2025 private placement after reaching the 35-patient enrollment milestone
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TALPHERA, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →